Doximity, Inc. (NASDAQ:DOCS) Director Timothy S. Cabral Sells 20,000 Shares

Doximity, Inc. (NASDAQ:DOCS) Director Timothy S. Cabral sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $57.62, for a total value of $1,152,400.00. Following the sale, the director now owns 6,360 shares in the company, valued at approximately $366,463.20. This trade represents a 75.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Doximity Stock Performance

Shares of Doximity stock opened at $58.14 on Thursday. Doximity, Inc. has a one year low of $22.96 and a one year high of $61.75. The company has a market capitalization of $10.85 billion, a PE ratio of 66.82, a P/E/G ratio of 4.68 and a beta of 1.39. The company has a 50-day simple moving average of $54.98 and a two-hundred day simple moving average of $45.22.

Doximity (NASDAQ:DOCS) last posted its earnings results on Thursday, November 7th. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.02). The firm had revenue of $136.83 million for the quarter, compared to analysts’ expectations of $127.05 million. Doximity had a net margin of 33.69% and a return on equity of 19.79%. During the same period in the previous year, the company earned $0.18 EPS. On average, equities analysts predict that Doximity, Inc. will post 0.88 earnings per share for the current fiscal year.

Institutional Trading of Doximity

Hedge funds and other institutional investors have recently made changes to their positions in the business. SBI Securities Co. Ltd. acquired a new position in Doximity during the 4th quarter valued at about $4,207,000. West Michigan Advisors LLC acquired a new position in shares of Doximity during the fourth quarter valued at about $306,000. US Bancorp DE raised its position in shares of Doximity by 7.8% in the 4th quarter. US Bancorp DE now owns 11,285 shares of the company’s stock valued at $603,000 after purchasing an additional 818 shares during the last quarter. Fielder Capital Group LLC boosted its stake in Doximity by 4.5% in the 4th quarter. Fielder Capital Group LLC now owns 5,488 shares of the company’s stock worth $293,000 after purchasing an additional 235 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. grew its position in Doximity by 13.1% during the 4th quarter. Oppenheimer Asset Management Inc. now owns 19,075 shares of the company’s stock worth $1,018,000 after purchasing an additional 2,212 shares during the last quarter. Hedge funds and other institutional investors own 87.19% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on DOCS. Mizuho started coverage on Doximity in a report on Wednesday, December 4th. They set a “neutral” rating and a $55.00 price target on the stock. JPMorgan Chase & Co. increased their target price on shares of Doximity from $30.00 to $48.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. The Goldman Sachs Group assumed coverage on shares of Doximity in a research note on Friday, November 15th. They set a “neutral” rating and a $58.00 price target for the company. Canaccord Genuity Group lowered shares of Doximity from a “buy” rating to a “hold” rating and increased their price objective for the stock from $40.00 to $60.00 in a research report on Wednesday, November 13th. Finally, Raymond James restated an “outperform” rating and set a $65.00 target price (up previously from $37.00) on shares of Doximity in a research report on Friday, November 8th. Thirteen research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $53.12.

About Doximity

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.